Mandate

Vinge has advised EQT AB (publ) in connection with the listing on Nasdaq Stockholm

Vinge has advised EQT in connection with the listing and also with the connected reorganization. 

The Vinge team primarily consisted of Dain Hård Nevonen, Erik Sjöman, Sofie Bjärtun, Joel Wahlberg, Hampus Olsson, Joel Magnusson and Emelie Svanberg (Capital Markets), Christina Kokko, Filip Öhrner, Karl Klackenberg, Christian Brelin and Christina Odengran (M&A and Restructuring), Louise Brorsson Salomon, Josefine Larsson, Ludvig Wettergren and Pauline Lagerstrand (Banking and Finance), Mattias Schömer, Henrik Wastenson and Victor Ericsson (Tax), Marcus Glader and Emma Johansson (Competition and Regulatory) and Olof Jisland and Valter Gran (EQT Foundation).
 

Sept. 24, 2019

Vinge advised ZetaDisplay on bond issue

The bonds are intended to be listed on Nasdaq Stockholm.
 
Vinge acted as legal adviser to ZetaDisplay. The Vinge team included partners Erik Sjöman and Christian Lindhé, and associates Fredrik Christiansson and Martin Svanberg.  

Sept. 12, 2019

Vinge advised Enea on directed share issue

The Vinge team was headed by capital markets and public M&A partners Erik Sjöman and Christian Lindhé and also included Nora Gullberg.
 

Aug. 26, 2019

Vinge advised in connection with Monterro’s acquisition of shares in Specops Software

Specops Software is a leading provider of password and authentication solutions.

The Vinge team included Erik Sjöman, Anna Edström and Daniel Melander Björner.

Aug. 21, 2019

Vinge advises Veoneer in connection with its USD 600 million capital raise 

Veoneer is listed on the New York Stock Exchange (NYSE:VNE) and on Nasdaq Stockholm (SSE: VNE SDB). 

Vinge advises Veoneer in relation to Swedish law. Vinge’s team mainly consist of Göran Nyström, Erik Sjöman, Malte Hedlund, Astrid Isberg, Stephanie Stiernstedt, Viktor Bergsten and Anders Sundin Lundberg. Maria Schultzberg advises on tax issues. 
 

May 23, 2019

Vinge advises Oriflame in connection with the offer from the af Jochnick family

The offer values Oriflame at approximately SEK 12.85 billion. 
  
Vinge advises the Independent Bid Committee of the Board of Directors of Oriflame. The Vinge team is headed by capital markets and public M&A partner Erik Sjöman.

May 22, 2019

Vinge advised Creades on its sale of shares in Lindab

Vinge advised Creades. The Vinge team was headed by capital markets and public M&A partner Erik Sjöman.
 

May 14, 2019

Vinge advises Cantargia on directed share issue

Vinge advises Cantargia. The Vinges team includes Erik Sjöman, Christian Lindhé and Ludvig Frithiof.

March 25, 2019

Vinge advises CGI on its offer for Acando

The total offer value for all outstanding shares in Acando amounts to approximately SEK 4,320 million.

Vinge advises CGI. The Vinge team includes Erik Sjöman, Malte Hedlund, Anna-Karin Alin, Anna Edström, Lena Lundahl, Marcus Glader, Trine Osen Bergqvist, Emma Johansson, Anna Grigorian and Victor Ericsson.

March 11, 2019

Vinge advises Fagerhult

After closing of the transaction, the intention is that Fagerhult will repay a bridge loan, raised to finance such part of the consideration that is not payable in Fagerhult shares, with the proceeds from a rights offering of approx. EUR 220 million.

Vinge and others advise Fagerhult. The Vinge team includes Erik Sjöman, Christian Lindhé and Ludvig Frithiof.

Jan. 8, 2019

Vinge advises Investor and the Knut and Alice Wallenberg Foundation in connection with Saab’s rights offering

Vinge advises Investor AB (Saab’s largest shareholder) and the Knut and Alice Wallenberg Foundation.

The Vinge team is headed by Erik Sjöman.
 

Nov. 20, 2018

Vinge advises Hansa Medical in connection with a directed share issue

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors, on the basis of an accelerated bookbuilding process conducted by Cowen, RBC Capital Markets and Skandinaviska Enskilda Banken.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg and Edin Agic. 
 

Nov. 15, 2018

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Oct. 29, 2018

Vinge advises Skånska Energi on the takeover bid by Kraftringen

The offer values Skånska Energi at around SEK 662 million. Vinge advises Skånska Energi.

The Vinge team is headed by capital markets and public M&A partner Erik Sjöman.

Oct. 2, 2018

Vinge advised Cantargia on its Nasdaq Stockholm main market listing

The Vinge team included Erik Sjöman, Christian Lindhé, Astrid Isberg and Martin Svanberg.

Sept. 25, 2018

Vinge advises Skånska Energi on the takeover bid by Infranode

The offer values Skånska Energi at around SEK 579 million. Vinge advises Skånska Energi.

The Vinge team is headed by capital markets and public M&A partner Erik Sjöman

Sept. 21, 2018

Vinge advised IBT on its Nasdaq Stockholm main market listing

 Vinge advised IBT.

The Vinge team included Erik Sjöman, Christian Lindhé and Astrid Karlsson..
 

Sept. 10, 2018

Vinge advises Skånska Energi on the takeover bid by Acsnacs

The offer values Skånska Energi at around SEK 497 million. Vinge advises Skånska Energi.

The Vinge team is headed by capital markets and public M&A partner Erik Sjöman

Sept. 7, 2018

Vinge advised BIMobject on directed share issue

Vinge advised BIMobject. The Vinge team included Erik Sjöman, Christian Lindhé and Astrid Karlsson.

July 11, 2018

Vinge advises ABG, SEB and Swedbank in connection with a directed share issue in Hemfosa

Hemfosa Fastigheter is a Swedish property company focused on community service properties in the Nordic region, with its largest tenants being the Swedish state and municipalities. Hemfosa’s common share has been listed since March 2014 and its preference share since December 2014, both on Nasdaq Stockholm.
 
Vinge’s team consists of Erik Sjöman, Dain Hård Nevonen and Sofie Bjärtun.
 

June 20, 2018

Vinge advises Nordea and SEB in relation to Better Collective’s listing on Nasdaq Stockholm

A prospectus was published on 28 May 2018 and the first day of trading on Nasdaq Stockholm is 8 June 2018. The total value of the offering amounts to approx. SEK 756 million, assuming that the over-allotment option is exercised in full.
 
Vinge’s team consist mainly of Jesper Schönbeck, Erik Sjöman, David Andersson, Amanda Knutsson, Rikard Lindahl and Stephanie Stiernstedt.

June 8, 2018

Vinge advises ABG Sundall Collier in connection with acquisition

Vinge’s team consisted of partners Erik Sjöman and Anna Edström.
 

May 8, 2018

Vinge advises Wilson Therapeutics in connection with the offer from Alexion


The offer values Wilson Therapeutics at approximately SEK 6,564 million. 
 
Vinge advises Wilson Therapeutics in connection with the offer. Vinge’s team is primarily composed of Erik Sjöman, Christian Lindhé, Astrid Karlsson and Philip Åberg. 

April 11, 2018

Vinge advises Enea

Vinge advises Enea. The Vinge team includes Erik Sjöman, Henrik Ossborn, Christian Lindhé, Fredrik Christiansson, Astrid Karlsson and Carl Öberg.
 

March 4, 2018

Vinge advises Active Biotech on rights offering

The Vinge team includes Erik Sjöman, Christian Lindhé, Astrid Karlsson and Jack Bengtsson.
 

Feb. 15, 2018

Vinge advised Medivir on its directed share issue

The Vinge team included Erik Sjöman, Christan Lindhé and Ludvig Frithiof.

Feb. 5, 2018

Vinge advises Tele2 in the merger with Com Hem

The combined company will be a leading integrated connectivity provider by combining an award-winning mobile network with the fastest national fixed network and the widest range of content in the market. The combination is conditional upon, inter alia, approval from the relevant competition authorities and approval of the merger from the shareholders in Tele2 and Com Hem. The merger is currently expected to be completed in the second half of 2018.

Vinge’s team primarily consists of Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Amanda Knutsson and Annika Nyberg Ekenberg (capital markets), Marcus Glader, Johan Karlsson, Emma Johansson, Grant McKelvey and Sebastian Örndahl (competition and regulatory), Louise Brorsson Salomon, Helena Håkansson and Lionardo Ojeda (financing) as well as Fredrik Dahl and Fredrik Gustafsson (employment).

Jan. 10, 2018

Vinge advises Wilson Therapeutics in connection with directed share issue

The share issue is directed to a number of selected institutions and sector specialist funds, internationally and in Sweden, on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Christian Lindhé, Erik Sjöman, Mattias Sköld, Ludvig Frithiof and Astrid Karlsson.

Dec. 12, 2017

Vinge advised Lifco on bond issue


The bonds were listed on Nasdaq Stockholm on 6 December 2017.

Vinge acted as legal advisor to Lifco. The Vinge team primarily consisted of Christian Lindhé and Carl Öberg, together with Erik Sjöman, Henrik Ossborn and Fredrik Christiansson.

 

Dec. 7, 2017

Vinge advises Erik Hemberg Fastighets AB on its mandatory offer for Götenehus

Erik Hemberg Fastighets AB has announced a mandatory public offer to the shareholders of Götenehus Group AB (publ). The negative bid premium offer values Götenehus at approximately SEK 402 million.

Capital markets and public M&A partner Erik Sjöman heads the Vinge team.

Dec. 1, 2017

Vinge advises Hansa Medical in connection with directed share issue

The share issue is directed to a number of selected international and Swedish reputable long-only investors and international sector specialist funds, on the basis of an accelerated bookbuilding process conducted by Evercore, RBC Capital Markets and SEB.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg, Sabina Börjesson and Ramin Baradaran.

Nov. 30, 2017

Vinge advises IBT on share issues

The Vinge team includes Erik Sjöman, Christian Lindhé, Kristoffer Franzkeit, Ludvig Frithiof and Astrid Karlsson.

Nov. 24, 2017

Vinge advises Cantargia on share issues

The Vinge team includes Erik Sjöman, Christian Lindhé, Kristoffer Franzkeit and Ludvig Frithiof.

Nov. 10, 2017

Vinge advised Orexo on bond issue

The bonds are intended to be listed on Nasdaq Stockholm.
 
Vinge acted as legal adviser to Orexo. The Vinge team included partners Erik Sjöman and Henrik Ossborn, and associates Christian Lindhé, Fredrik Christiansson and Astrid Karlsson.  
 

Nov. 2, 2017

Vinge advised Enea on directed share issue

The Vinge team was headed by capital markets and public M&A partner Erik Sjöman and included Christan Lindhé and Astrid Karlsson.

Oct. 26, 2017

Vinge advises Trianon 

Vinge’s team primarily consisted of Erik Sjöman, Anna Edström, Christian Lindhé and Astrid Karlsson.

June 26, 2017

Vinge advises Generic Sweden AB (publ) on the sale of Generic Systems Sweden AB

Generic Sweden's divestment of the consultancy business focuses the group's operations towards telecom. The purchase price consists of a cash component and shares in MSC Group AB (publ), which is listed on Nasdaq OMX Stockholm Small Cap.

The Vinge team advising Generic Sweden includes partners Jesper Ottergren (M&A) and Erik Sjöman (Capital Markets).

June 21, 2017

Vinge advises Medicover in relation to its listing on Nasdaq Staockholm

Trading in Medicover’s B share on Nasdaq Stockholm commences today, 23 May 2017. The price in the offering was set at SEK 56 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 7.5 billion. Assuming full exercise of the over-allotment option in the offering, the value of the offering will amount to approximately SEK 2.3 billion.

Medicover is a leading international healthcare and diagnostic services provider in Poland, Germany, Romania, Ukraine and certain other markets, primarily in Central and Eastern Europe (“CEE”). Additionally, Medicover is in the process of entering the fast-growing Indian healthcare market in order to expand its geographical footprint and further leverage its emerging markets capabilities. Medicover offers a broad range of healthcare services and a significant hub-and-spoke diagnostic laboratory network, supported by extensively developed proprietary software and information systems infrastructure. Medicover operates through two divisions: Healthcare Services and Diagnostic Services.

Vinge’s team primarily consists of Dain Hård Nevonen, Erik Sjöman, Ludvig Frithiof, Sofie Bjärtun, Louise Nordkvist and Astrid Karlsson.

May 23, 2017

Vinge advised Creades on its investment in Apotea

The investment by Creades amounts to a total of SEK 120.5 million.
 
Vinges team consisted of Erik Sjöman and Jesper Ottergren.
 

April 28, 2017

Vinge advised Medivir on share redemption offering

Medivir AB (publ) (Nasdaq Stockholm) has completed a share redemption offering of approx. SEK 870 million to Medivir’s shareholders.

The Vinge team was headed by capital markets and public M&A partner Erik Sjöman and included Rikard Lindahl and Malte Hedlund.

March 20, 2017

Vinge advised Enea on directed share issue

Vinge has advised Enea AB (publ) in connection with a directed share issue of SEK 162.4 million through an accelerated book-building procedure.

The Vinge team was headed by capital markets and public M&A partner Erik Sjöman and included Christan Lindhé and Astrid Karlsson.

Feb. 28, 2017

Vinge assisted EQT V Limited in connection with sale of shares in AcadeMedia AB (publ)

Vinge assisted EQT V Limited (”EQT”) in connection with the sale of shares in AcadeMedia AB (publ) (”AcadeMedia”) through an accelerated bookbuilding process carried out on 13 February 2017. In total, 12 million shares were placed at a price of SEK 58 per share, corresponding to a total value of SEK 696 million. Following the transaction, EQT holds approximately 41.6% of the shares in AcadeMedia.

Vinge’s team consisted of Dain Hård Nevonen, Erik Sjöman and Sofie Bjärtun.

Feb. 20, 2017

Vinge advised BIMobject on the investment by Solar

BIMobject AB (publ) has resolved on a directed placement of new shares of around SEK 166.7 million to Danish Solar A/S. Solar also acquires existing shares in BIMobject of around SEK 50.4 million.

Vinge (capital markets and public M&A partner Erik Sjöman and senior associate Fredrik Christiansson) advised BIMobject.

Jan. 31, 2017

Vinge advises Creades in connection with Altor’s offer for Transcom

Altor has announced a public cash offer to the shareholders of Transcom WorldWide AB. The offer values Transcom at around SEK 2,294 million.

Vinge (capital markets and public M&A partner Erik Sjöman) advises Creades, which is one of Transcom’s largest shareholders and which has undertaken to accept the offer subject to certain conditions.

Dec. 21, 2016

Vinge advises Cantargia on rights offering

Vinge advises Cantargia AB (publ) (Nasdaq First North) in connection with a rights offering of approximately SEK 91 million.

The Vinge team includes Erik Sjöman, Christian Lindhé, Kristoffer Franzkeit and Ludvig Frithiof.

Dec. 21, 2016

Vinge advised Investor in connection with the IPO of Alligator

Alligator Bioscience AB (publ) was listed on the main market of Nasdaq Stockholm with the first day of trading being 23 November 2016. The price in the initial public offering was SEK 32.50 per share, corresponding to a total value of the company’s shares of approx. SEK 2,275 million. Investor AB, through Duba AB, was one of the two selling shareholders.
 
Vinge advised Investor. The Vinge team was headed by capital markets and public M&A partner Erik Sjöman.

Nov. 23, 2016

Vinge advises Carnegie and Nordea in connection with the listing of Volati on Nasdaq Stockholm

Vinge advises Carnegie Investment Bank AB (publ) and Nordea Bank AB (publ) who are acting as Joint Global Coordinators and Joint Bookrunners in connection with the listing of the common shares and preference shares in Volati AB (publ) on Nasdaq Stockholm. The company has applied for the company’s shares to be admitted for trading and Nasdaq Stockholm has approved the company’s shares for listing subject to customary conditions. A prospectus is expected to be published on or around 18 November 2016 and first day of trading is expected to be on or around 30 November 2016.

Volati is an industrial group comprising 13 business units organised into three business areas: Trading, Industry and Consumer. Volati has some 40 operating companies in 15 countries, with Sweden accounting for the largest share of net sales. Acquisitions are central in Volati’s strategy and Volati primarily acquires companies with proven business models, leading market positions and strong cash flows at reasonable valuations, and develops these with an emphasis on long-term creation.   

Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Sofie Bjärtun.

Nov. 17, 2016

Vinge advises Active Biotech on rights offering

Active Biotech AB (publ) (Nasdaq Stockholm) carries out a rights issue of approximately SEK 55 million.
 
Vinge advises Active Biotech. Vinge’s team primarily consists of Erik Sjöman, Christian Lindhé, Ludvig Frithiof and Astrid Karlsson.

Nov. 15, 2016

Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma

Medivir AB (publ) (Nasdaq Stockholm) has entered into an agreement with Karo Pharma AB (publ) (Nasdaq Stockholm) regarding the sale of Medivir’s subsidiary BioPhausia (Nordic Brands) to Karo Pharma. The purchase price is SEK 908 million and the transaction is expected to close by mid-December 2016.
 
Vinge advises Medivir. The Vinge team includes Erik Sjöman, Anna Edström, Mattias Sköld, Dain Hård Nevonen, Rikard Lindahl and Ludvig Frithiof, and Fredrik Dahl and Sara Strandberg (employment law).

Nov. 3, 2016

Vinge assisted Active Biotech in licensing deal regarding ANYARA

Vinge has assisted Active Biotech AB (publ.) in entering into a development and licensing agreement with NeoTX Therapeutics Ltd (”NeoTX”) regarding Active Biotech’s investigational compound ANYARA. NeoTX will be responsible for the worldwide clinical development and commercialization of the drug for cancer indications.
 
Vinge’s team consisted of Erik Sjöman and Kristoffer Franzkeit.

Oct. 27, 2016

Vinge advises Nordnet in connection with the takeover bid from the Öhman Group and Nordic Capital

The Öhman Group, the main owner of Nordnet, and Nordic Capital have, through NNB Intressenter AB, made a public offer to the shareholders of Nordnet AB (publ) (Nasdaq Stockholm). The Offer values all shares of Nordnet at SEK 6,476 million.
 
Vinge advises Nordnet. The Vinge team is headed by capital markets and public M&A partner Erik Sjöman and includes Malte Hedlund, Pernilla Warg and Christoffer Widström.

Oct. 25, 2016

Vinge advises Hansa Medical in connection with directed share issue

The share issue is directed to selected international specialist investors as well as Swedish institutional and strategic investors. The issue proceeds will primarily be used to finance the development process of the drug candidate IdeS up to an application for market authorization of IdeS for treatment in connection with kidney transplantation. The share issue is fully subscribed for in accordance with agreements executed with the selected investors. Shareholders representing approximately 45 percent of Hansa Medical’s shares and votes have undertaken to vote in favor of the board’s proposal for the share issue at an extraordinary general meeting.

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team consists of Dain Hård Nevonen, Erik Sjöman and Nils Fredrik Dehlin.

Oct. 24, 2016

Vinge has advised the Swedish state in connection with its sale of shares in SAS

In total, 23 million ordinary shares held by the Swedish and Norwegian governments were placed at a price of SEK 15.50 per share, equivalent to an aggregate value of approximately MSEK 357.  Following the transaction, the Swedish government holds 17.2 per cent of the ordinary shares and 17.1 per of the votes in SAS.

Vinge’s team consisted of partners Charlotte Levin and Eric Sjöman together with associates Amanda Knutsson and David Andersson.

Oct. 12, 2016

Vinge advised Elanders

Vinge has advised Elanders AB (publ) in connection with the acquisition of the German supply chain management company LGI Logistics Group International GmbH and advises in connection with the rights issue of approximately SEK 700 million that is made to partly finance the acquisition.

Vinge’s team includes Erik Gabrielson, Erik Sjöman, Christian Lindhé, Ludvig Frithiof and Astrid Karlsson.

Sept. 2, 2016

Vinge advises SAF-HOLLAND on its takeover bid for Haldex

SAF-HOLLAND S.A. (Frankfurt Stock Exchange), through a wholly-owned subsidiary, has announced an all-cash offer to the shareholders of Haldex AB (publ) (Nasdaq Stockholm). The total offer value for all outstanding shares in Haldex amounts to SEK 4,165 million.
 
Vinge advises SAF-HOLLAND. The Vinge team is headed by capital markets and public M&A partner Erik Sjöman and includes Anders Strid, Jo-Anna Nordström, Ludvig Frithiof and Astrid Karlsson, and Henrik Ossborn and Fredrik Christiansson (financing).

July 14, 2016

Vinge advises AcadeMedia in relation to its listing on Nasdaq Stockholm

Vinge advises AcadeMedia AB (publ) and selling shareholders in relation to AcadeMedia’s listing on Nasdaq Stockholm. Trading in the AcadeMedia share on Nasdaq Stockholm commences today, June 15 2016. The price in the offering was set at SEK 40 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 3,764 million. Assuming the over-allotment option is exercised in full, the value of the offering will amount to approximately SEK 1,093 million.

AcadeMedia is the leading and single largest independent education provider in northern Europe. In 2014/15, approximately 62,000 children and students attended AcadeMedia’s preschools, compulsory schools and upper secondary schools. An additional 80,000 individuals participated in AcadeMedia’s adult education courses. In 2014/15, AcadeMedia had approximately 400 preschools, compulsory schools and upper secondary schools in Sweden and Norway and approximately 150 adult education units in Sweden. AcadeMedia also has seven preschools in the Munich region of Germany. AcadeMedia has operations throughout the education chain, from preschool, compulsory school and upper secondary school to adult education.

Vinge’s team primarily consists of Erik Sjöman, Dain Hård Nevonen, Christian Lindhé, Ludvig Frithiof, Sofie Bjärtun, Nils Fredrik Dehlin and Astrid Karlsson. Maria Schultzberg and Emelie Parland advise on tax matters.

June 15, 2016

Vinge advised Creades on share redemption offering

Creades AB (publ) (Nasdaq Stockholm) has completed a share redemption offering to the shareholders, through which approximately SEK 158 million was distributed to the shareholders. Vinge advised Creades.

The Vinge team consisted of Erik Sjöman and Jo-Anna Nordström.

May 16, 2016

Vinge advised Wilson Therapeutics in connection with its IPO

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

May 12, 2016

Vinge advises IBT on rights offering

Infant Bacterial Therapeutics AB (publ) (IBT) carries out a rights offering of SEK 100 million. Vinge advises IBT.

The Vinge team primarily consists of Erik Sjöman and Dain Hård Nevonen (partners, capital markets & public M&A) and associates Ludvig Frithiof, Joel Wahlberg and Astrid Karlsson, and Tora Hansjons (tax).

April 28, 2016

Vinge advises BioGaia and its subsidiary Infant Bacterial Therapeutics in connection with a share distribution and separate listing

Vinge advises BioGaia AB (publ) and its subsidiary Infant Bacterial Therapeutics AB (publ) ("IBT") in connection with the proposed distribution of BioGaia’s shares in IBT to the shareholders of BioGaia. In connection with the distribution, IBT will apply for listing of the company's series B shares on Nasdaq First North. IBT is developing a drug (IBP-9414) against necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Vinge's team consists of Erik Sjöman, Dain Hård Nevonen, Ludvig Frithiof and Joel Wahlberg. Tora Hansjons advises on tax matters.

Feb. 15, 2016

Vinge advises Mylan on its offer for Meda

Mylan N.V. has announced a recommended public offer to the shareholders of Meda AB (publ) to tender all their shares in Meda to Mylan. The total offer consideration consists of a combination of cash and Mylan ordinary shares. At announcement, the total value of the offer for all Meda shares, including Meda net debt, is approximately SEK 83.6 billion or USD 9.9 billion.
 
In connection with the offer, Mylan has retained Vinge as legal advisor in Sweden. The Vinge team is led by public M&A partners Erik Sjöman and Charlotte Levin and also includes Rikard Lindahl, Anna Edström and Malte Hedlund (on M&A matters), Mikael Ståhl, Louise Brorsson Salomon and Albert Wållgren (on finance matters), Fredrik Gustafsson (on compensation and benefits matters) and Maria Schultzberg (on tax matters).

Feb. 12, 2016

Vinge advises Randstad on its takeover bid for Proffice

Randstad Nordic AB, a company owned by Randstad Holding nv (NYSE Euronext Amsterdam), has announced a recommended cash offer to the shareholders of Proffice AB (publ) (Nasdaq Stockholm). The total offer value for the outstanding shares in Proffice amounts to SEK 1,648 million.
 
Vinge advises the bidder. The Vinge team is headed by capital markets and public M&A partner Erik Sjöman. Other team members include Anna Edström, Jo-Anna Nordström, Mattias Sköld, Malte Hedlund and Susanne Samuelsson as well as Pär Remnelid and Ina Lunneryd (competition law) and Fredrik Dahl and Sara Strandberg (employment law).

Nov. 30, 2015

Vinge advises JCE and Tequity on their joint bid for Cybercom

Viltor AB, a company owned by JCE Group Aktiebolag and Tequity AB, has announced a recommended cash offer to the shareholders of Cybercom Group AB (publ) (Nasdaq Stockholm). The offer values Cybercom at around SEK 541 million.
 
Vinge advises the joint bidders. The Vinge team is headed by M&A partner Magnus Pauli and capital markets and public M&A partner Erik Sjöman. Other team members include Jo-Anna Nordström, Anna Palmérus, Karin Wisenius, Mikael Ståhl, Natalie Bäck and Malte Hedlund.

Nov. 2, 2015

VINGE ADVISES PANDOX IN RELATION TO ITS LISTING ON NASDAQ STOCKHOLM

Vinge advises Pandox Aktiebolag (publ) in relation to its listing on Nasdaq Stockholm. A prospectus was published on 8 June 2015 and the first day of trading on Nasdaq Stockholm was 18 June 2015. The price in the offering was set at SEK 106 per share, corresponding to a market value of all shares issued by Pandox of SEK 15,900 million. The total value of the offering amounts to SEK 6,360 million, assuming that the over-allotment option is exercised in full.

Pandox is a leading owner of hotel properties located in Northern Europe with focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio comprises 104 hotels in the upper medium- and upscale segment with a total of 21,969 hotel rooms across eight countries. The market value of Pandox’s property portfolio amounted to SEK 27 billion as of 31 March 2015.

Vinge’s team consisted mainly of Jesper Schönbeck, Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Adam Sandberg and Ludvig Berke. Marie Brommesson assisted in due diligence, including financing and property related matters, and Maria Schultzberg and Tora Hansjons assisted in tax related matters.

June 18, 2015

Vinge advised Creades on share redemption

Creades AB (publ) (Nasdaq Stockholm) has completed a share redemption offering to the shareholders, through which approximately SEK 143 million was distributed to the shareholders. Vinge advised Creades.

The Vinge team consisted of Erik Sjöman, Jo-Anna Nordström and Rikard Lindahl.

June 5, 2015

Vinge advises Oriflame in relation to the groups change of domicile from Luxembourg to Switzerland

Vinge advises Oriflame in connection with the process of changing the group’s domicile from Luxembourg to Switzerland. As part of this process, Oriflame Holding AG, a wholly owned Swiss subsidiary of Oriflame Cosmetics S.A., has announced a share-for-share exchange transaction. The shares of Oriflame Holding are intended to be listed on the main market of Nasdaq Stockholm.

Erik Sjöman and Dain Hård Nevonen (partners, capital markets & public M&A) and Sabina Börjesson and Joel Wahlberg advise Oriflame. Mattias Schömer (partner, tax) and Tora Hansjons provide tax advice.

May 8, 2015

Vinge advised Orexo on its divestment of Kibion

Orexo AB (publ) (Nasdaq Stockholm) has divested its subsidiary Kibion to a group of investors. Vinge advised Orexo.

The Vinge team included Erik Sjöman (partner, capital markets and M&A) and associates Christian Lindhé, Kristoffer Franzkeit and Cecilia Cronqvist.

May 4, 2015

Vinge advised Lifco on bond issue

Lifco AB (publ) (Nasdaq Stockholm) has issued three-year unsecured bonds of in total SEK 1,050 million. The bonds are to be listed on Nasdaq Stockholm.                     
 
Vinge acted as legal adviser to Lifco. The Vinge team included partners Erik Sjöman (capital markets and public M&A) and Henrik Ossborn (banking & finance), and associates Christian Lindhé (capital markets and public M&A), Fredrik Christiansson (banking & finance) and Ludvig Frithiof (capital markets and public M&A).


 

March 25, 2015

Vinge advises the largest shareholders of Axis in connection with Canon’s takeover bid

Canon Inc. has made a public cash offer to the shareholders of Axis AB (publ). The offer values Axis at approximately SEK 23.6 billion. The three largest shareholders of Axis, holding in aggregate approximately 39.5 per cent of the total number of shares and votes in Axis, have undertaken to accept the offer, subject to certain conditions.
 
Vinge advises the three largest shareholders. The Vinge team is headed by Peter Bäärnhielm and also includes Erik Sjöman and Dain Nevonen.

Feb. 10, 2015

Vinge advises Active Biotech on rights offering

Active Biotech AB (publ) (Nasdaq Stockholm) carries out a rights offering of SEK 225 million. Vinge advises Active Biotech.

The Vinge team primarily consists of Erik Sjöman (partner, capital markets & public M&A) and associates Christian Lindhé, Ludvig Frithiof and Madelene Eriksson.

Nov. 24, 2014

Vinge advises Medivir on share redemption programme

Medivir AB (publ) (Nasdaq Stockholm) has resolved on a voluntary share redemption programme of SEK 625 million.

Vinge advises Medivir. The Vinge team primarily consists of Erik Sjöman (partner, capital markets & public M&A) and Rikard Lindahl.

Nov. 24, 2014

Vinge advised Lifco on IPO

The class B shares of Lifco AB (publ) have been admitted to trading on the main market of Nasdaq Stockholm, following an offering to the general public in Sweden and to institutional investors in Sweden and abroad. The price in the offering was SEK 93 per share, corresponding to a market value of all Lifco shares of approximately SEK 8.4 billion.

Vinge advised Lifco. The Vinge team primarily consisted of Erik Gabrielson, Erik Sjöman, Jesper Schönbeck, Anna Edström and Christian Lindhé, together with a large number of other associates and specialist partners.

Nov. 21, 2014

VINGE ADVISES ADVENICA IN CONNECTION WITH LISITNG ON FIRST NORTH

Vinge has advised Advenica AB (publ) in connection with its listing on NASDAQ OMX First North Premier.

Vinge’s team primarily consisted of partners Jesper Ottergren and Erik Sjöman together with associates Christian Lindhé, Carl Fahleryd and Kristoffer Franzkeit.

Sept. 19, 2014

Vinge advised Orexo on private placement

Orexo AB (publ) (NASDAQ OMX Stockholm) has completed a private placement of Orexo shares to qualified investors, resulting in total cash proceeds of approximately SEK 346.5 million before transaction costs.

Vinge acted as legal adviser to Orexo. The Vinge team included Erik Sjöman (partner, capital markets and public M&A) and associates Christian Lindhé, Rikard Lindahl and Madelene Eriksson.

 

 

Sept. 4, 2014

Vinge has assisted Landsbanki Islands hf, London Branch

Vinge has assisted Landsbanki Islands hf, London Branch in connection with a debt restructuring, refinancing and acquisition financing of Sistema Holding.

Vinges team consisted of Henrik Ossborn, Erik Sjöman, Fredrik Christiansson and Susanne Samuelsson".

July 30, 2014

Vinge advised Morgan Stanley in connection with Volkswagen’s offer for Scania

Morgan Stanley and Deutsche Bank were financial advisers to the Independent Committee of the Board of Directors of Scania AB (publ) in connection with Volkswagen’s offer for Scania.
 
Vinge advised Morgan Stanley. The Vinge team included capital markets and public M&A partners Göran Nyström, Peter Bäärnhielm and Erik Sjöman.

June 5, 2014

VINGE ADVISES CARLSON INC.

Vinge is advising Carlson Inc. in connection with Rezidor Hotel Group AB’s new share issue of approximately MEUR 60. Carlson, which is a global hotel and travel group, and one of the largest privately owned companies in the US, owns approximately 51 per cent of Rezidor and has undertaken to subscribe for its pro rata share of the new issue. Rezidor Hotel Group is listed on NASDAQ OMX Stockholm, Mid cap.

Vinge’s team consists of Göran Nyström, Jo-Anna Nordström and Erik Sjöman.

May 12, 2014

Vinge advised in Elanders’ rights offering

Elanders AB (publ) (NASDAQ OMX Stockholm) has made a SEK 125 million fully underwritten rights offering. Vinge advised Elanders.

The Vinge team included partners Erik Gabrielson and Erik Sjöman and associates Christian Lindhé and Madelene Eriksson.

May 11, 2014

Vinge advised Orexo on bond issue

Orexo AB (publ) (NASDAQ OMX Stockholm) has issued a four-year senior unsecured bond loan of SEK 500 million, with the possibility to issue a further SEK 500 million of bonds. The bonds are to be listed on NASDAQ OMX Stockholm.                      

Vinge acted as legal adviser to Orexo. The Vinge team included partners Erik Sjöman (capital markets and public M&A) and Henrik Ossborn (banking & finance), and associates Christian Lindhé (capital markets and public M&A) and Fredrik Christiansson (banking & finance).

May 2, 2014

Vinge advises Kistefos in its mandatory bid for TransAtlantic

Kistefos AS has announced a mandatory bid for Rederi AB Transatlantic, where Kistefos is already the largest shareholder. The bid values TransAtlantic at around SEK 739 million. Vinge advises Kistefos.

The Vinge team consists mainly of partner Erik Sjöman and associates Jo-Anna Nordström and Rikard Lindahl.

March 26, 2014

Vinge represents Solidium in connection with SSAB’s combination with Rautaruukki

SSAB AB (publ) (NASDAQ OMX Stockholm) has made a recommended public share exchange offer for Rautaruukki Oyj (NASDAQ OMX Helsinki). Rautaruukki’s largest shareholder is Solidium Oy, which is wholly owned by the State of Finland. Upon completion of the combination, Solidium will become a major shareholder of the combined group, together with SSAB’s current largest shareholder, Industrivärden. The total value of the share exchange offer amounts to SEK 10.1 billion (EUR 1.1 billion). 

Vinge represents Solidium in matters relating to Swedish law. The Vinge team consists of capital markets and public M&A partners Göran Nyström and Erik Sjöman

Jan. 24, 2014

VINGE ADVISES CREADES IN CONNECTION WITH ITS LISTING ON NASDAQ OMX STOCKHOLM’S MAIN MARKET

Creades AB (publ) (NASDAQ OMX First North) has been approved for listing on NASDAQ OMX’s main market. The first day of trading was 6 December 2013.

Vinge’s team primarily consisted of partner Erik Sjöman and associates Jo-Anna Nordström, Christian Lindhé and Rikard Lindahl. Associates Maria Schultzberg and Maria Doeser advised in relation to tax matters.

Dec. 5, 2013

Vinge advises bong in connection with new issues

Bong AB (publ) (NASDAQ OMX Stockholm) has carried out a fully underwritten rights issue, a directed placement of convertible bonds to certain qualifying investors and set-off issues to certain creditors. The aggregate amount issued is approximately SEK 475 million.  Vinge advised Bong.

Vinge’s team primarily consisted of Erik Sjöman, Peter Oscarsson, Christian Lindhé, Fabian Ekeblad, Albert Wållgren and Henrik Jonsson.

Oct. 14, 2013

Vinge advises MultiQ International AB on the acquisition of Public Systems Nordic AB

Vinge advises MultiQ International AB, listed on Nasdaq OMX Small Cap, in connection with the acquisition of Public Systems Nordic AB and the SEK 15m new issue of shares with preferential rights conducted in connection with the acquisition. Through the acquisition, Sweden’s largest company within monitor solutions for public spaces, so called Digital Signage, is created. The purchase price for the acquisition of Publiq is paid through the issuance of new shares in MultiQ.

The Vinge team advising MultiQ International AB includes partner Jesper Ottergren and, among others, associates Marcus Bergdahl and Christian Lindhé. Further, partner Erik Sjöman provides advice on capital markets regulations and Ingela Malmborg provides employment law advice.

Aug. 30, 2013

Vinge advises the board of Trygga Hem in connection with public takeover offer by Sector Alarm

Vinge is advising the board of Trygga Hem Scandinavien AB in connection with Sector Alarm’s recommended public takeover offer in respect of all shares in Trygga Hem for SEK 18 per share, which is equivalent to a total of SEK 192.6 million.

Trygga Hem is a nationwide security company and one of Sweden’s largest suppliers of home alarms and villa alarms to private customers. Trygga Hem’s shares are listed on NASDAQ OMX First North Stockholm.

Vinge’s team consisted of partner Erik Sjöman and associates Dain Nevonen and Jo-Anna Nordström.

June 18, 2013

Vinge advises Active Biotech in relation to directed new share issue

In March this year, Active Biotech AB (publ) conducted a directed new share issue to Investor AB (publ) pursuant to which Active Biotech procured SEK 270 million.

Vinge’s team consisted of partner Erik Sjöman and associate Christian Lindhé.

April 4, 2013

Vinge advises on division of Creades

On the initiative of the majority shareholders, Bioinvestor and Pan Capital, it is proposed that Creades (NASDAQ OMX First North) will be divided into two companies pursuant to a squeeze out procedure whereby 30 per cent of Creades’ net worth will be transferred to a new, unlisted company, Sedarec, which will be distributed to the shareholders in the manner desired by them. Pan Capital will become the majority shareholder in Sedarec which, following completion of the squeeze out procedure, will be liquidated under Pan Capital’s management, whereas Creades, with Bioinvestor as its majority shareholder, will continue its long-term strategy.

Vinge team advising Creades primarily consisted of partner Erik Sjöman and associate Jo-Anna Nordström.

Jan. 24, 2013